Back to top
more

AMAG Pharmaceuticals, Inc. (AMAG)

(Delayed Data from NSDQ)

$11.07 USD

11.07
385,891

+0.36 (3.36%)

Updated Dec 6, 2019 04:00 PM ET

After-Market: $11.05 -0.02 (-0.18%) 6:24 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.62%
17.69%
9.40%
5.11%
2.01%
10.65%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

A Value | D Growth | F Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Brokerage Reports

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for AMAG

   

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

0 items in cart

INDUSTRY: Medical - Biomedical and Genetics

Reports for Purchase

Showing records 161 - 180 ( 28995 total )

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 161

11/25/2019

Daily Note

Pages: 12

Details cannot be displayed until the posted date of availability

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Available: 12/10/2019

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 162

11/25/2019

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 163

11/25/2019

Industry Report

Pages: 8

Our Holiday Gift: Join Our mRNA, NASH, Acromegaly, Enteric Hyperoxaluria Calls

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 164

11/25/2019

Company Report

Pages: 6

Ximino Tracker - Week ending 11/15/2019

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 165

11/25/2019

Industry Report

Pages: 8

Our Holiday Gift: Join Our mRNA, NASH, Acromegaly, Enteric Hyperoxaluria Calls

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Alcobra Ltd.

Industry: Medical - Biomedical and Genetics

Record: 166

11/25/2019

Industry Report

Pages: 8

Our Holiday Gift: Join Our mRNA, NASH, Acromegaly, Enteric Hyperoxaluria Calls

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Vascular Biogenics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 167

11/25/2019

Company Report

Pages: 35

VB-111 Targeting Ovarian Cancer with Dual Mechanism of Action - Initiation of Coverage

Provider: Roth Capital Partners, Inc.

Analyst: ISAACSON J

Price: 75.00

Research Provided by a Third Party

Company: Vascular Biogenics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 168

11/25/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Alcobra Ltd.

Industry: Medical - Biomedical and Genetics

Record: 169

11/25/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: The Medicines Company

Industry: Medical - Biomedical and Genetics

Record: 170

11/25/2019

Company Report

Pages: 7

Got Its Christmas Wish Granted Early With Novartis Takeout

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Magenta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 171

11/25/2019

Daily Note

Pages: 6

Details cannot be displayed until the posted date of availability

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Available: 12/10/2019

Research Provided by a Third Party

Company: Intercept Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 172

11/25/2019

Company Report

Pages: 7

Details cannot be displayed until the posted date of availability

Provider: Wedbush Securities Inc.

Analyst: MOUSSATOS L

Price: 25.00

Available: 12/10/2019

Research Provided by a Third Party

Company: Ultragenyx Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 173

11/25/2019

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Intercept Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 174

11/25/2019

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: INmune Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 175

11/25/2019

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Clovis Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 176

11/25/2019

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 177

11/25/2019

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 178

11/25/2019

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Wize Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 179

11/25/2019

Company Report

Pages: 5

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Chiasma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 180

11/25/2019

Industry Report

Pages: 8

Our Holiday Gift: Join Our mRNA, NASH, Acromegaly, Enteric Hyperoxaluria Calls

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party